| Literature DB >> 26852957 |
Xianjie Wen1, Shiyuan Xu2, Qingguo Zhang3, Xiaohong Li4, Hua Liang1, Chenxiang Yang1, Hanbing Wang1, Hongzhen Liu1.
Abstract
Cav3.1 is a low-voltage-activated (LVA) calcium channel that plays a key role in regulating intracellular calcium ion levels. In this study, we observed the effects of lidocaine hydrochloride on the pshRNA-CACNA1G-SH-SY5Y cells that silenced Cav3.1 mRNA by RNA interference, and investigated the roles of p38 MAPK in these effects. We constructed the pNC-puro-CACNA1G-SH-SY5Y cells and pshRNA-CACNA1G -SH-SY5Y cells by the RNA interference. All the cells were cultured with or without 10mM lidocaine hydrochloride for 24 h. The cell morphology, cell viability, Cav3.1 and p38 protein expression, cell apoptosis rate and intracellular calcium ion concentration were detected. We found that all cells treated with 10mM lidocaine hydrochloride for 24 h showed cellular rounding, axonal regression, and cellular floating. Compared with the cells in SH-SY5Y+Lido group and NC+Lido group, those in the RNAi+Lido group showed similar changes, but of smaller magnitude. Additionally, following lidocaine hydrochloride all cells displayed increased Cav3.1 and p38 MAPK protein, apoptosis rate, and intracellular calcium ion levels; however,these changes in the RNAi+Lido group were less pronounced than in the SH-SY5Y+Lido and NC+Lido groups. The cell viability decreased following lidocaine hydrochloride treatment, but viability of the cells in the RNAi+Lido group was higher than in the SH-SY5Y+Lido and NC+Lido groups. The results showed that Cav3.1 may be involved in neuronal injury induced by lidocaine hydrochloride and that p38 MAPK phosphorylation was reduced upon Cav3.1 gene silencing.Entities:
Keywords: 2-(4-Amidinophenyl)−6-indolecarbamidine dihydrochloride (PubChem CID: 160166; Calcium ion (PubChem CID: 271); Cav3.1; Lidocaine hydrochloride; Lidocaine hydrochloride (PubChem CID: 6314); Propidium iodide (PubChem CID: 104981); SH-SY5Y cells; p38 MAPK
Mesh:
Substances:
Year: 2016 PMID: 26852957 DOI: 10.1016/j.ejphar.2016.02.019
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432